CV Therapeutics Again Declines Astellas $16 Per Share Purchase Offer
This article was originally published in PharmAsia News
Executive Summary
Less than a month after Astellas made public its bid to purchase CV Therapeutics for $16 a share for a total price of nearly $1 billion, CVT turned down the offer Feb. 20 as "significantly undervaluing" the biotech and not serving the best interests of the company or its stockholders